Zimmer Biomet Holdings, Inc. Stock Swiss Exchange

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Delayed Swiss Exchange 03:17:28 2024-04-24 EDT 5-day change 1st Jan Change
113 CHF +15.31% Intraday chart for Zimmer Biomet Holdings, Inc. +3.67% +15.31%

Financials

Sales 2024 * 7.76B 6.93B 10.62B Sales 2025 * 8.12B 7.25B 11.11B Capitalization 22.19B 19.8B 30.36B
Net income 2024 * 998M 891M 1.37B Net income 2025 * 1.2B 1.07B 1.64B EV / Sales 2024 * 3.42 x
Net Debt 2024 * 4.32B 3.86B 5.92B Net Debt 2025 * 2.99B 2.67B 4.09B EV / Sales 2025 * 3.1 x
P/E ratio 2024 *
22.1 x
P/E ratio 2025 *
19.1 x
Employees 18,000
Yield 2024 *
0.89%
Yield 2025 *
0.9%
Free-Float 64.77%
More Fundamentals * Assessed data
Dynamic Chart
Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors CI
Zimmer Biomet Enters Co-Marketing Deal With RevelAi Health MT
RevelAi Health and Zimmer Biomet Holdings, Inc. Announce Exclusive Multi-Year Co-Marketing Agreement to Advance Value-Based Care and Health Equity Through AI-Powered Technology CI
Transcript : Zimmer Biomet Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
Zimmer Biomet Enters Distribution Agreement with THINK Surgical to Offer TMINI Miniature Handheld Robotic System for Total Knee Arthroplasty CI
Osteal Therapeutics, Inc. announced that it has received $50 million in funding from Zimmer Biomet Holdings, Inc., Johnson & Johnson Innovation - JJDC, Inc., HM Capital Management, LLC, GIDEON STRATEGIC PARTNERS LLC and other investors CI
Zimmer Biomet Holdings Insider Sold Shares Worth $1,474,582, According to a Recent SEC Filing MT
Zimmer Biomet's Limited Exposure to High-Growth Markets Spurs Revenue Concerns, UBS Says MT
Barclays Adjusts Price Target on Zimmer Biomet to $125 From $130 MT
Barclays Adjusts Price Target on Zimmer Biomet Holdings to $125 From $130 MT
Zimmer Biomet Outlines Growth Strategy Through 2027; Board Approves $2 Billion Stock Buyback MT
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $2,000 million worth of its shares. CI
Transcript : Zimmer Biomet Holdings, Inc. - Analyst/Investor Day
Zimmer Biomet Holdings, Inc. authorizes a Buyback Plan. CI
Osteal Therapeutics, Inc. announced that it expects to receive funding CI
More news
1 day+15.31%
1 week+3.67%
3 months+15.31%
6 months+15.31%
Current year+15.31%
More quotes
1 week
109.00
Extreme 109
113.00
1 month
109.00
Extreme 109
113.00
Current year
98.00
Extreme 98
113.00
1 year
97.00
Extreme 97
113.00
3 years
97.00
Extreme 97
160.00
5 years
97.00
Extreme 97
160.00
10 years
86.00
Extreme 86
160.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 18-10-31
Director of Finance/CFO 55 19-06-30
Chief Tech/Sci/R&D Officer - 21-06-06
Members of the board TitleAgeSince
Director/Board Member 68 06-12-31
Director/Board Member 68 08-12-31
Director/Board Member 51 14-12-11
More insiders
Date Price Change
24-06-21 109 -.--%
24-06-20 109 -.--%
24-06-19 109 -.--%
24-06-18 109 -.--%
24-06-17 109 -.--%

Delayed Quote Swiss Exchange, April 24, 2024 at 03:17 am

More quotes
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
107.9 USD
Average target price
136.4 USD
Spread / Average Target
+26.44%
Consensus